Bristol-Myers Squibb (BMY) Announces Positive Data from the Phase 3 SCOUT-HCM Trial of Camzyos

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best pharma stocks to invest in now. Bristol-Myers Squibb Company (NYSE:BMY) announced on March 29 positive data from the Phase 3 SCOUT-HCM trial of Camzyos, which marks the first study of a cardiac myosin inhibitor (CMI) in adolescents aged 12 years to <18 years with symptomatic obstructive hypertrophic cardiomyopathy. The company reported that the SCOUT-HCM trial met its primary endpoint, exhibiting a clinically meaningful and statistically significant reduction from baseline in Valsalva left ventricular outflow tract gradient at Week 28 with Camzyos compared to placebo.

UBS Boosts Bristol-Myers Squibb (BMY) Price Target as Milvexian Data Looms

Bristol-Myers Squibb Company (NYSE:BMY) also reported that Camzyos demonstrated meaningful improvement over placebo in multiple secondary endpoints at 28 weeks, adding that similar safety findings were observed in the Camzyos and placebo groups. Management stated that the data is being presented as a late-breaking clinical trial presentation at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo 2026, with simultaneous publication in The New England Journal of Medicine.

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers, develops, and delivers advanced medicines for serious diseases. Its medicines fall into various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience.

While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.